Evotec SE (NASDAQ:EVO - Get Free Report) shares gapped up before the market opened on Friday . The stock had previously closed at $4.03, but opened at $4.58. Evotec shares last traded at $4.72, with a volume of 288,664 shares trading hands.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on EVO shares. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a research report on Thursday, April 24th. Royal Bank of Canada restated an "outperform" rating on shares of Evotec in a report on Thursday, May 15th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Evotec has a consensus rating of "Hold" and an average price target of $5.93.
Get Our Latest Research Report on EVO
Evotec Trading Down 7.5%
The business's fifty day moving average price is $3.76 and its two-hundred day moving average price is $4.18. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09.
Hedge Funds Weigh In On Evotec
Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new position in shares of Evotec in the 4th quarter valued at approximately $27,000. CSS LLC IL bought a new position in shares of Evotec in the fourth quarter worth about $50,000. Bank of America Corp DE increased its position in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares during the period. Lighthouse Investment Partners LLC bought a new position in Evotec during the fourth quarter worth $166,000. Finally, ABC Arbitrage SA bought a new position in Evotec during the first quarter valued at about $260,000. 5.81% of the stock is currently owned by institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Articles
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
